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Department of Chemical and Biological Engineering, University of Colorado, Boulder, ColoradoABSTRACT The efficacy of cancer drugs such as cisplatin (Cp) and oxaliplatin (Ox), which covalently bind to DNA to form
drug-DNA adducts, is linked to their recognition by repair proteins such as HMGB1a. Previous experimental studies showed
that HMGB1a’s binding affinity for Cp- and Ox-DNA varies with the drug used and the local DNA sequence context of the adduct.
We link this differential binding affinity to the free energy of deforming (bending and minor groove opening) the drug-DNA mole-
cule during HMGB1a binding. Specifically, the minimal binding affinity of HMGB1a for Ox-DNA in the TGGA context is explained
by its larger deformation free energy compared with Cp-DNA or Ox-DNA in other sequence contexts. Methyl groups on neigh-
boring thymine bases in Ox-TGGA crowd the minor groove and sterically hinder the motion of the diaminocyclohexane ring of
Ox, leading to this reduced deformability and resultant decrease in HMGB1a’s binding affinity.INTRODUCTIONPlatinum-based anticancer drugs, such as cisplatin (Cp) and
oxaliplatin (Ox), are widely and successfully used to treat
cancer (1,2). This class of drug damages DNA by covalently
binding to adjacent purine bases to form drug-DNA adducts,
which prevent replication proteins from accessing the
genetic code and hence lead to cell death (1,2). Unfortu-
nately, tumor cells can develop resistance to Cp, reducing
its effectiveness; however, tumor cells often remain sensitive
to Ox despite the similar structure and mode of action of the
two drugs (2,3). The causes of this differential tolerance are
not completely understood, but cellular damage recognition
and mismatch repair systems have been implicated (4).
Often, differential drug resistance arises because some of
the repair proteins involved in these systems display greater
binding affinity for Cp than for Ox (5,6). One particular
damage recognition protein, the high-mobility group protein
B1 (HMGB1), has been studied in great detail because the A-
domain of this protein (HMGB1a) is amodel for other HMG-
class DNA-binding motifs, which are common in cellular
repair mechanisms (7,8).
Most experimental work has focused on consecutive
guanines damaged by the platinum-based drugs, because
these are the most common adducts (1). The binding affinity
of HMGB1a for these adducts depends on both the identity
of the drug and the bases flanking the damaged guanines
(i.e., the sequence context). Although the binding affinity
of HMGB1a for Cp adducts (Cp-DNA) has been studied
in numerous sequence contexts, Ox adducts (Ox-DNA) have
only been studied in a small subset of the possible sequence
contexts (AGGC, CGGA, TGGA, and TGGT). For Cp,
it has been found that the binding affinity proceeds in
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0006-3495/12/05/2331/8 $2.00CGGA ¼ TGGA > TGGT > AGGC (5,6,9,10). For Ox,
the binding affinity proceeds in a different order: TGGT >
AGGC ¼ CGGA >> TGGA (5,6). Most remarkably, Ox
in the TGGA context (Ox-TGGA) is essentially unrecog-
nized by HMGB1a and has a dissociation constant (KD)
similar to that of undamaged B-DNA (5). However, we
note that there is some disagreement among previous ex-
perimental studies; for instance, the KD for Cp-TGGA esti-
mated by Dunham and Lippard (9) differs by an order of
magnitude from that reported by Wei et al. (5). Differences
such as these qualitatively change the ordering of the
binding affinities for Cp, which clearly complicates quanti-
tative comparisons (see Table S1 in the Supporting Material
for additional details and a possible methodological reason
for these discrepancies). In all cases of conflict, however,
the discrepancies in binding affinity correspond to differ-
ences of less than the thermal energy between the two
results, indicating that the resolution of the gel mobility shift
assay used to obtain these data may be too low to resolve the
differences accurately. In light of these conflicting results,
we sought to understand the most striking experimental
result: the absolute lack of recognition of Ox-TGGA.
In a previous study we focused on the structure and
conformational dynamics of Cp and Ox adducts in different
sequences (11). First, we found that the ensemble average
structure of the HMGB1a-bound drug-DNA was indepen-
dent of both sequence and drug identity, confirming that
the protein-bound drug-DNA structure cannot explain the
differential recognition. Next, examining the drug-DNA
molecules in the absence of the protein HMGB1a, we found
that the ensemble average structural distributions explain
only some of the differences in binding affinity. Ensemble
averages do suggest a possible explanation for the poor re-
cognition of Ox-TGGA. A large dihedral angle between
the damaged guanine bases (also known as the roll angle)
is considered favorable for binding because it more easilydoi: 10.1016/j.bpj.2012.04.013
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between the damaged bases, and low twist at the binding site
is considered favorable because the HMGB1a-bound drug-
DNA is unwound with respect to undamaged B-DNA. At
least one of these two structural characteristics (i.e., roll
or twist) is favorable for Ox in the AGGC, CGGA, and
TGGT sequences, whereas both roll and twist are unfavor-
able for Ox-TGGA. This provides a plausible case for
the weak recognition of Ox-TGGA, but it is not entirely
convincing given that the same structural argument does
not explain the strong recognition of Ox-TGGT. In keeping
with previous simulation studies (12–14), we observed con-
formational dynamics associated with transient hydrogen
bonds that explained some other experimental trends.
However, a number of experimental observations remained
unexplained, not least of which was the particularly poor
recognition of Ox-TGGA. It became apparent that many
features, such as the overall bend angle and minor groove
width of the drug-damaged DNA structure in the absence
of the protein (termed unbound in this work) is intermediate
between the undamaged B-DNA and protein-drug-DNA
(termed bound here) structures (Fig. 1, a and b). This
suggests that the protein must deform the drug-DNA struc-
ture substantially during binding (Fig. 1 c). Given that
sequence-dependent curvature and flexibility are well-
known properties of DNA (15,16), we hypothesized thatFIGURE 1 The frequency of the helical bend (a) and minor groove width
(b) of the unbound drug-DNA structure is intermediate between that of
B-DNA and drug-DNA when bound to HMGB1a. (c) Single snapshot of
structures of B-DNA, unbound drug-DNA, and drug-DNA when bound to
HMGB1a protein. The unbound drug-DNA structure is substantially
different from the B-DNA structure. This unbound drug-DNA structure is
further substantially deformed during binding by HMGB1a. DGdeform
corresponds to the free energy required to deform the unbound drug-
DNA structure to the drug-DNA structure when bound to HMGB1a,
calculated in the absence of the protein.
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cule and/or high-energy barrier in the kinetic pathway
from the unbound to the bound state could explain the
lack of recognition of Ox-TGGA. As such, we chose to em-
ploy computationally intensive, biased molecular-dynamics
(MD) simulations and free-energy calculations to determine
the free-energy landscape of Cp-DNA and Ox-DNA in
various sequence contexts as a function of reaction coordi-
nates that represent the deformation states.MATERIALS AND METHODS
Fig. 1 c illustrates that DGdeform is the free energy needed to deform the
drug-DNA from the unbound structure to the bound structure. In principle,
one could calculate the overall free energy of HMGB1a binding to drug-
DNA molecule using a molecular mechanics Poisson-Boltzmann/surface
area (MMPBSA) (17), free-energy perturbation (18), or thermodynamic
integration (19) method; however, these methods are plagued by low accu-
racy in entropy calculations for such large molecules, or have difficulty in
achieving sufficient sampling for large systems with large conformational
changes between the initial and final states. Because we hypothesize that
the deformability of the DNA depends on the drug and the sequence
context, we focused purely on calculating DGdeform, which is a component
of the overall free energy of binding, using atomistic MD simulations
combined with umbrella sampling, followed by the weighted histogram
analysis method (WHAM) (20). Details of our MD protocol are available
in Section S2, and details of the umbrella sampling procedure are presented
below.
To determine the free-energy landscape, one must define the configura-
tional space, identify reaction coordinate(s) that define the configurational
space, and ensure sufficient sampling of structures at all values of the reac-
tion coordinate(s), including those that the system rarely samples in tradi-
tional unbiased MD simulations (21–24). Based on our knowledge of the
system at hand (Fig. 1, a and b), we chose two reaction coordinates to define
the configurational space: the minor groove width and the helical bend
angle. We chose these coordinates because our previous work showed
that the most notable changes that occur during protein-drug-DNA binding
are the helix bending and the minor groove widening, although the exact
order in which these changes occur is not known. Fig. 2 qualitatively illus-
trates the definition of these reaction coordinates. The first reaction coordi-
nate, the minor groove width, is defined as the distance between the center
of mass between two groups of backbone atoms, as shown in Fig. 2 a. One
of these groups comprises the backbone atoms of one of the guanine bases
linked to the drug and base 30 of that guanine, and the other group comprises
the backbone atoms of the cytosine basepaired with the other drug-bonded
guanine and base 30 of that cytosine. The selection of backbone atoms
excludes hydrogen atoms. The constraint was applied with the distance
collective variable in the NAMD 2.8 colvars module (25). This reaction
coordinate is the same as that described by Zacharias (24). The second reac-
tion coordinate, the helical bend angle, is defined as the angle between the
top four basepairs of the DNA (red in Fig. 2 b) and the bottom four base-
pairs (green in Fig. 2 b). When applying the helical bend angle constraint,
we maintain a 12-basepair canonical B-DNA structure aligned with the
z axis as the reference unbent state. The top four basepairs are constrained
to a certain angle with respect to this unbent reference structure by
a harmonic potential, using the tilt collective variable, whereas the bottom
four basepairs are constrained to maintain the same orientation as their
counterparts in the reference structure, using the orientationAngle collec-
tive variable. Mathematically, the projection (i.e., the scalar product) of
the z axis of the top four basepairs onto the z axis of the reference structure
is constrained to a certain value (e.g., 1 to maintain perfect alignment, or
0.707 for an angle of 45). The z axis of the top four basepairs is determined
after a best-fit rotation to fit the reference structure, but no rotational
FIGURE 2 The reaction coordinates (a) minor groove width, defined as
the distance between the centers-of-mass of the two groups of atoms shown
here in van der Waals representation, and (b) the helical bend angle defined
as the angle between the vector representing the top four basepairs and the
corresponding basepairs in an unbent reference structure. The bottom four
basepairs (b) are constrained to the same orientation as the corresponding
basepairs in an unbent reference structure. The combination of the restraints
on the top and bottom basepairs causes the DNA to bend. (Best viewed in
color.)
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pairs, the best-fit rotation that maintains the orientation with the reference
structure is constrained to the unit quaternion (i.e., no rotation around any
axis). We do not need to control the direction of the bend because the DNA
is predisposed to bend toward the major groove, the same direction as when
HMGB1a binds to DNA. To our knowledge, this definition of a bending
reaction coordinate for umbrella sampling has not been reported in
literature, but it is similar in nature to other DNA bending reaction coordi-
nates (21,22).
To enable sufficient sampling of all structural states, we employed the
umbrella sampling method (26), which introduces a series of biasing poten-
tials at discrete points along the reaction coordinate(s). We combined the
results from multiple simulations with different biasing potentials (where
each individual simulation is referred to as a window) using WHAM
(20,27,28). Initially, we performedone-dimensional (1D) umbrella sampling
with only the helical bend constraint. We confirmed that the 1D free-energy
profiles as a function of the helical bend angle qualitatively reproduced
known trends in flexibility for A-tract DNA, and that the free-energy profiles
essentially converged with the amount of sampling we performed (see
Fig. S2 andFig. S3 for details). To understand the differential binding affinity
of HMGB1a to the various drug-DNA molecules, the free-energy profile as
a function of helical bend angle alone is insufficient. This is because the
helical bend angle alone cannot describe the complete configurational space
that represents the deformation of the drug-DNAmolecule, as during binding
the protein not only bends the helix but alsowidens theminor groove. There-
fore, we subsequently performed two-dimensional (2D) umbrella samplingto determine the entire free-energy surface in terms of the helical bend and
the minor groove width. Additional details regarding both the 1D and 2D
umbrella sampling procedures are provided in Section S3.
We note certain limitations with regard to the force field used in this work
and its impact on our free-energy calculations. First, a previous simulation
study by Mazur (29) revealed that the persistence length of DNA as param-
eterized in the Amber force field is ~80 nm, rather than the typically cited
value of 50 nm. Although the apparently greater stiffness of the DNAmodel
may quantitatively affect our results, we believe our results are at least qual-
itatively accurate because 1), Mazur (29) did not include the recent bsc0
modification used in this work, which better represents the backbone
torsion angles and in turn may alter the flexibility of the DNA model;
and 2), although there are quantitative differences between the Amber force
field and experimental measurements, the differences appear within the
range of variations observed with different experimental approaches and
solvent conditions (29). Therefore, it seems likely that the Amber force field
will produce qualitatively correct results regarding DNA deformability in
this work. Second, it is not known how the choice of a different force field
to parameterize DNA (e.g., CHARMM) will affect the results of our free-
energy calculations. However, recent comparisons of the Amber and
CHARMM force fields suggest that they produce very similar results
(30,31). It seems plausible that, despite quantitative differences among
the various biomolecular force fields, our major qualitative findings would
be preserved.
Once we had obtained the free-energy surfaces, we employed the finite-
temperature string (FTS) method (32) to find the minimum free-energy
pathway (MFEP) between the unbound and bound structures on the free-
energy landscapes resulting from 2D umbrella sampling conducted in the
absence of the protein. The original zero-temperature string (ZTS) method
can be used to find the MFEP on smooth free-energy surfaces where the
MFEP literally follows the lowest free-energy values between two or
more energy minima (33,34). The ZTS method places a series of points
(the string) on the free-energy surface and allows them to evolve according
to the gradient of the free energy, analogously to an unbiased MD simula-
tion. However, on rough free-energy surfaces where the roughness is on
the order of the thermal energy, the literal MFEP may not be informative
because the small-scale details (roughness) of the free-energy surface are
unimportant. For example, consider a wide, shallow, free-energy tube
connecting two minima but with sinusoidal roughness of much smaller
amplitude than thewalls of the tube or the depth of theminima: qualitatively,
the MFEP should be near the center of the tube, not the long, winding path
that avoids the insignificant localmaxima of the roughness. The FTSmethod
solves this issue by augmenting the ZTS method with a random force with
magnitude similar to the roughness of the surface, analogously to Langevin
dynamics. This random force allows the points of the string to overcome
minor energy barriers and reach amore reasonableMFEP on rough surfaces.
We chose the FTS method to calculate MFEPs because the free-energy
surfaces we calculated in this work are not entirely smooth. For our
purposes, the initial and final points of the MFEP were fixed at the structural
coordinates of the unbound and bound systems from our previous unbiased
simulations of the unbound drug-DNA molecule and the HMGB1a-drug-
DNA complex, respectively (11). Additional details regarding our imple-
mentation of the FTS method are available in Section S3.
Using previous experimental results for the binding affinity of HMGB1a
for various DNA sequences, we calculated dissociation constants (KD)
using a method described in the literature (13). Subsequently, we used these
KD values to estimate the relative binding energy of HMGB1a for Cp versus
Ox using the method detailed in Section S4.RESULTS AND DISCUSSION
1D deformability
First, we calculated the 1D free energy as a function of
helical bend angle, and the results are presented in Fig. 3.Biophysical Journal 102(10) 2331–2338
FIGURE 3 Free energy of bending (kcal/mol)
for B-DNA, Cp-DNA, and Ox-DNA in four
sequence contexts: (a) TGGT, (b) TGGA, (c)
AGGC, and (d) CGGA. The dashed vertical lines
correspond to the average helical bend angle of
the drug-DNA structure from Elder and Jayaraman
(11), and the dotted vertical lines correspond to the
average helical bend angle of the structure of the
drug-DNAwhen bound to HMGB1a protein. Sym-
bols on these vertical lines denote either Cp
(circles) or Ox (squares).
TABLE 1 Free energy of bending in kcal/mol (DGdeform,1D) and
the difference in bending free energy of Cp and Ox
(DDGdeform,1D)
Sequence DGdeform,1D Cp DGdeform,1D Ox DDGdeform,1D (Cp-Ox)
AGGC 1.14 0.94 0.21
CGGA 1.14 1.18 0.04
TGGA 1.73 2.37 0.64
TGGT 1.27 1.57 0.30
DDGdeform,1D is negative when it is easier to bend Cp-DNA than Ox-DNA.
Note that DDGdeform,1D is low for all sequences except for TGGA, in agree-
ment with experimental results showing that HMGB1a easily distinguishes
Ox-TGGA from Cp-TGGA and from other sequence contexts.
2334 Elder and JayaramanMost notably, we observe large differences between B-DNA
(no drug) and the drug-DNA structures. Clearly, the cova-
lent binding of the drug inherently bends the DNA, thereby
shifting the minima in the free energy of bending to higher
bend angles. The minima of the free-energy curves coincide
quantitatively with the average bend from unbiased drug-
DNA simulations from our previous structural studies
(11). The free-energy profile is roughly quadratic for small
perturbations but increases linearly for large deformations,
in agreement with previous work that focused on the
sequence-dependent deformability of B-DNA (21,35).
There are no free-energy barriers along the profile, which
is reasonable because bending DNA in the absence of the
protein is unfavorable. The presence of the protein during
binding would provide additional favorable enthalpic in-
teractions that would make the total binding free energy
favorable. However, because here we are simply calculating
the free-energy cost for bending the drug-DNA molecule in
the absence of the protein (DGdeform), the resulting shape
of the free-energy curve as a function of helical bend is
reasonable.
Table 1 shows the 1D bending free-energy change
between the unbound and bound states, DGdeform,1D, and
the difference in this free-energy change between Cp-
DNA and Ox-DNA, DDGdeform,1D. If DDGdeform,1D is nega-Biophysical Journal 102(10) 2331–2338tive, it simply implies that it is easier to bend Cp-DNA than
Ox-DNA. Experimental results suggest that HMGB1a has
a more favorable binding affinity for Cp-DNA than for
Ox-DNA. Although DDGdeform,1D for the two drugs in the
AGGC, CGGA, and TGGT contexts is too low to clearly
distinguish the drugs from each other in these contexts, in
the TGGA context we find that DDGdeform,1D is much
greater, offering some evidence for the much weaker recog-
nition of Ox in this context. Next, we examine the effect of
sequence context for the Cp- and Ox-DNA adducts (see Cp
and Ox columns of Table 1). For Cp-DNA, the variations in
DGdeform,1D with sequence context do not correspond to the
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although we reiterate that the reported differences in exper-
imentally observed binding affinity are relatively small and
may not be discernible. For Ox-DNA, DGdeform,1D is great-
est for the TGGA context, further explaining the weak
recognition by HMGB1a. However, Ox-TGGT has the
second-highest DGdeform,1D and yet is known to have the
highest binding affinity. Hence, we conclude that the 1D
free-energy profile is insufficient to explain all binding
affinity trends, and turn to the more-comprehensive 2D
umbrella sampling procedure.2D deformability
Fig. 4 shows frequency distributions from unbiased simula-
tions and 2D free-energy landscapes for Cp-TGGA and Ox-
TGGA as a function of helical bend angle and minor groove
width. The frequency distributions (Fig. 4, a and b) show the
most common structure in the unbound state and the bound
state. These distributions are used to identify the initial
(I) and final (F) coordinates in the free-energy landscapes.
The free-energy landscapes (Fig. 4, c and d) show thatFIGURE 4 Frequency distributions of the structural parameters from
unbiased simulations for (a) Cp- and (b) Ox-TGGA, and 2D free-energy
landscapes of deformation for (c) Cp- and (d) Ox-TGGA. The frequency
distributions (a and b) were calculated from the combined series of bend
angle and minor groove width values visited by both the unbound and
bound structures in unbiased simulations. The free-energy landscapes
(c and d) were calculated via umbrella sampling and WHAM, as described
in the text. White and gray dotted lines are MFEPs from the unbound struc-
ture (marked I) to the bound structure (marked F). The multiple MFEPs
denote paths calculated from the mean values of the unbound state (I) to
multiple endpoints in the bound state (F). The y coordinate of each endpoint
(F) is the mean value of the minor groove width. The x coordinate of the
endpoint (F) of the white path is the mean value of the bend angle, and
the x coordinates of the gray paths are the mean5 SD of the bend angle.
Contour lines are spaced 1 kcal/mol apart. White regions indicate the
absence of data.helical bend and minor groove width are correlated because
the free energy increases more gradually when the two coor-
dinates increase in tandem, which is expected because we
also observed the positive correlation of helical bend and
minor groove width in our structural studies (11). As with
the 1D bending free-energy profiles, the 2D landscapes
are relatively smooth and lack free-energy barriers. We
also find that the drugs have qualitatively different free-
energy landscapes, with Ox-DNA generally experiencing
a greater increase in free energy with bend angle than Cp.
Fig. S4 and Fig. S5 show the free-energy landscapes for
all drug and sequence combinations, and Fig. S6 confirms
that the 2D free-energy landscapes essentially converged
with the amount of sampling we performed. We note that
the application of these two global structural constraints
also results in many of the same local structural deforma-
tions associated with the binding of HMGB1a, such as the
increase in the roll angle between the damaged guanine
bases, which suggests that this choice of reaction coordi-
nates is reasonable.
Fig. 4, c and d, also show multiple MFEPs within each
landscape. These multiple MFEPs correspond to the path
with different final endpoints (marked as F in Fig. 4, c
and d) to allow an assessment of the sensitivity of our find-
ings to the structure of the bound state. The MFEPs in Fig. 4,
c and d, correspond to three different final structural states:
the white pathway ends at the mean values of helical bend
(x coordinate) and minor groove width (y coordinate),
whereas the two gray pathways end at the mean5 standard
deviation (SD) of the probability distribution of the helical
bend (x coordinate) and the mean of the minor groove width
(y coordinate). These structural coordinates of the helical
bend angle and minor groove width were obtained from
our previous study (11). The initial point of the pathway
(marked as I in Fig. 4) is the same in all cases because
that region of the landscape is quite shallow, and conse-
quently changes in the initial structure cause only small
changes in the initial energy. We also calculated MFEPs
ending at the mean 5 SD of the probability distribution
of the minor groove width (y coordinate) and mean of the
bend angle (x coordinate), but we found that the free-energy
values along these pathways (termed free-energy profiles)
did not differ significantly from the pathway ending at
the mean structural values (i.e., the white pathways in
Fig. 4, c and d). We also found that the profiles are insensi-
tive to small deviations in the specific pathway taken by
calculating the free-energy profile of a linear pathway
between the initial and final states, which produces a free-
energy profile similar to that produced by the MFEP
(Fig. S7). Consequently, we focus on the three free-energy
profiles along the MFEPs ending at the mean 5 SD of the
helical bend (x coordinate) and the mean minor groove
width (y coordinate).
Fig. 5 shows the free-energy values along the points of
the MFEPs calculated for all drugs and sequence contextsBiophysical Journal 102(10) 2331–2338
FIGURE 5 Free-energy profiles along the MFEP of each drug and
sequence combination. Bold lines correspond to MFEPs ending at the
mean structure of the bound state (white pathways in Fig. 4). Dotted lines
correspond to the MFEPs ending at the mean bend angle 5 SD of the
bend angle and at the mean minor groove width (gray pathways in
Fig 4.). The x axis indicates the progress along the pathway, with the
unbound state being 0.0 and the bound state being 1.0.
TABLE 2 Relative free energy (kcal/mol) of HMGB1a binding
to Cp versus Ox
Sequence (reference) KD ratio DDGbind from KD ratio DDGdeform,2D
AGGC (6) 2.6 0.56 0.10
CGGA (6) 3.2 0.69 0.13
TGGA (5) 55.1 2.39 0.87
TGGT (6) 1.8 0.35 0.39
Values are calculated from experimental binding affinity data (DDGbind
from KD ratio) and from 2D deformability umbrella sampling calculations
(DDGdeform,2D). DDG is the difference in 2D deformation energy between
Ox and Cp, i.e., a negative value indicates that deforming Cp-DNA is easier
than deforming Ox-DNA.
FIGURE 6 Position of thymine methyl groups (Me1 and Me2) relative to
Cp and Ox in the TGGA and TGGT contexts. It is qualitatively evident that
the bulky diaminocyclohexane moiety of Ox is pinched between the two
methyl groups in the TGGA context (a), which hinders deformation of
Ox-TGGA, whereas the smaller amine groups of Cp do not interact strongly
with the methyl groups (b). Ox is less constrained by the two methyl groups
in the TGGT context (c) than in the TGGA context (a).
2336 Elder and Jayaraman(i.e., free-energy profiles). The bold lines are for the MFEP
ending at the mean structural coordinates (like the white
pathways in Fig. 4, c and d) and the dotted lines are for
the MFEPs ending at the mean 5 SD of the helical bend
(like the gray pathways in Fig. 4, c and d). For Cp-DNA,
it is not possible to distinguish the sequence contexts
because the SD profiles largely overlap the mean profiles
of the sequence contexts. However, the situation is quite
different for Ox-DNA: although the SD profiles of the
AGGC, CGGA, and TGGT sequences essentially overlap
each other, the TGGA sequence reaches significantly higher
free energies throughout the pathway and does not overlap
the other sequences. This provides the strongest evidence
yet for the extremely low binding affinity of HMGB1a for
Ox-TGGA.
Table 2 shows the differences in 2D deformability free-
energy changes for Cp and Ox (DDGdeform,2D), alongsideBiophysical Journal 102(10) 2331–2338the overall free-energy differences calculated from ex-
perimental binding affinity data (DDGbind). We note that a
quantitative comparison between the simulation and exper-
imental data is not possible because the experimental data
measure the binding free energy of HMGB1a (DGbind),
whereas the simulation method calculates only the free en-
ergy of deformation of the drug-DNA molecule (DGdeform)
in the absence of the protein. However, qualitative com-
parisons are still valid. The differences in DGdeform between
Cp-DNA and Ox-DNA are less than the thermal energy in
the AGGC, CGGA, and TGGT contexts, and therefore it
may not be possible to distinguish these contexts as dis-
cussed above. However, the TGGA context shows a much
more significant discrepancy between Cp and Ox, in agree-
ment with the experimental findings for DDGbind.
The cause of this striking difference between Cp- and
Ox-TGGA appears to be steric clashes between the bulky
diaminocyclohexane ring of Ox and methyl groups on
nearby thymine bases (the thymine of TGGA and thymine
paired opposite the A of TGGA), as shown in Fig. 6. Methyl
groups on these thymine bases extend into the already
crowded minor groove even in undamaged B-DNA. These
methyl groups were previously shown to alter the flexibility
of both undamaged and drug-damaged DNA by interacting
Sequence-Specific Recognition of Cancer 2337with each other in consecutive A-T basepairs or by sterically
hindering a platinum-based drug with a bulky chemical
group (36,37). The TGGA and TGGT contexts contain
two such methyl groups, one on either side of the adduct,
and these groups pinch the diaminocyclohexane ring of
Ox but do not interact closely with the smaller amine groups
of Cp. This is visually evident when one compares the
trajectories, and we verified this observation by quantifying
the distance between the platinum atom of the drugs and the
adjacent methyl groups along the MFEPs. The platinum
atom was chosen as a measure of how closely each drug
interacts with the methyl groups, because both Cp and Ox
contain this feature. In the TGGT context, both Cp and
Ox adducts maintain a distance of ~5 A˚ from both methyl
groups in both the unbound and bound states, suggesting
that Cp-TGGT and Ox-TGGT present a similar hindrance
during binding (and deformation). In the TGGA context,
Cp maintains distances of 5 A˚ and 9 A˚ from the two methyl
groups in both the unbound and bound states. Ox maintains
the same close contact of 5 A˚ with the methyl group imme-
diately 50 of the adduct (Me1 in Fig. 6) in the unbound and
bound states, but the distance to the methyl group on the
opposite DNA strand (Me2 in Fig. 6) decreases from 9 A˚
to 5 A˚ between the unbound and bound states. This decrease
in distance indicates that Ox interacts more closely with the
methyl Me2 in the bound state, and this closer interaction
causes a steric hindrance that makes it more difficult to
deform Ox-TGGA than Ox in other contexts. The increased
difficulty of deformation is likely a major contributor to the
lower binding affinity of HMGB1a for Ox-TGGA. In
contrast to TGGA, the CGGA context possesses only the
methyl group on the strand opposite the drug-DNA adduct
(equivalent to Me2 in the TGGA context), and both drugs
maintain a platinum-methyl distance of ~9 A˚, indicating
lower steric hindrance during deformation of both Cp-
CGGA and Ox-CGGA.CONCLUSIONS
In this work, we calculated the free energy of deformation of
DNA damaged by the cancer drugs Cp and Ox in several
DNA sequence contexts. The results of this study suggest
that the greater free-energy penalty for deforming Ox in
the TGGA context (compared with Cp and other sequence
contexts) is responsible for the extremely low binding
affinity of HMGB1a for Ox-TGGA. This result stands in
contrast to previous studies that suggested that structure is
the key factor in differential binding affinity, but is fully
consistent with findings that deformability often plays
a crucial role in protein-binding affinity (37–39). The reason
for the sequence-dependent deformation free energy of
Ox-DNA adducts appears to be steric hindrance by nearby
thymine methyl groups, the locations of which depend on
the sequence context. Recent efforts focused on steric
hindrance between the drug and DNA (40–42), and thework presented here further support the idea that in the
future, designers of cancer drugs could focus on tuning re-
pair protein binding by tailoring this type of steric hindrance
with adjacent methyl groups.SUPPORTING MATERIAL
Ten sections, including six figures and references (43–52), are available at
http://www.biophysj.org/biophysj/supplemental/S0006-3495(12)00457-2.
This research was supported in part by the National Science Foundation
through TeraGrid resources provided by Kraken under grant number
TG-MCB100140. This work also used the Janus supercomputer, which is
supported by the National Science Foundation (award number CNS-
0821794) and the University of Colorado Boulder. The Janus supercom-
puter is a joint effort of the University of Colorado Boulder, the University
of Colorado Denver, and the National Center for Atmospheric Research.REFERENCES
1. Jamieson, E. R., and S. J. Lippard. 1999. Structure, recognition, and
processing of cisplatin-DNA adducts. Chem. Rev. 99:2467–2498.
2. Wang, D., and S. J. Lippard. 2005. Cellular processing of platinum anti-
cancer drugs. Nat. Rev. Drug Discov. 4:307–320.
3. Woynarowski, J. M., S. Faivre,., P. E. Juniewicz. 2000. Oxaliplatin-
induced damage of cellular DNA. Mol. Pharmacol. 58:920–927.
4. Chaney, S. G., S. L. Campbell,., Y. Wu. 2005. Recognition and pro-
cessing of cisplatin- and oxaliplatin-DNA adducts. Crit. Rev. Oncol.
Hematol. 53:3–11.
5. Wei, M., S. M. Cohen, ., S. J. Lippard. 2001. Effects of spectator
ligands on the specific recognition of intrastrand platinum-DNA
cross-links by high mobility group box and TATA-binding proteins.
J. Biol. Chem. 276:38774–38780.
6. Malina, J., O. Novakova, ., V. Brabec. 2007. Conformation of DNA
GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric
analog. Biophys. J. 93:3950–3962.
7. Huang, J. C., D. B. Zamble, ., A. Sancar. 1994. HMG-domain
proteins specifically inhibit the repair of the major DNA adduct of
the anticancer drug cisplatin by human excision nuclease. Proc. Natl.
Acad. Sci. USA. 91:10394–10398.
8. Pilch, D. S., S. U. Dunham,., K. J. Breslauer. 2000. DNA sequence
context modulates the impact of a cisplatin 1,2-d(GpG) intrastrand
cross-link on the conformational and thermodynamic properties of
duplex DNA. J. Mol. Biol. 296:803–812.
9. Dunham, S. U., and S. J. Lippard. 1997. DNA sequence context and
protein composition modulate HMG-domain protein recognition of
cisplatin-modified DNA. Biochemistry. 36:11428–11436.
10. Cohen, S. M., Y. Mikata,., S. J. Lippard. 2000. HMG-domain protein
recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-
rich sequence contexts. Biochemistry. 39:11771–11776.
11. Elder, R. M., and A. Jayaraman. 2012. Role of structure and dynamics
of DNA with cisplatin and oxaliplatin adducts in various sequence
contexts on binding of HMGB1a. Mol. Simul. In press.
12. Sharma, S., P. Gong,., S. G. Chaney. 2007. Molecular dynamic simu-
lations of cisplatin- and oxaliplatin-d(GG) intrastrand cross-links
reveal differences in their conformational dynamics. J. Mol. Biol.
373:1123–1140.
13. Ramachandran, S., B. R. Temple, ., N. V. Dokholyan. 2009. Struc-
tural basis for the sequence-dependent effects of platinum-DNA
adducts. Nucleic Acids Res. 37:2434–2448.
14. Bhattacharyya, D., S. Ramachandran,., S. G. Chaney. 2011. Flanking
bases influence the nature of DNA distortion by platinum 1,2-
intrastrand (GG) cross-links. PLoS ONE. 6:e23582.Biophysical Journal 102(10) 2331–2338
2338 Elder and Jayaraman15. Stefl, R., H. Wu, ., J. Feigon. 2004. DNA A-tract bending in three
dimensions: solving the dA4T4 vs. dT4A4 conundrum. Proc. Natl.
Acad. Sci. USA. 101:1177–1182.
16. Parkinson, J. A., Y. Chen, ., P. J. Sadler. 2000. Sequence-dependent
bending of DNA induced by cisplatin: NMR structures of an A.T-rich
14-mer duplex. Chemistry. 6:3636–3644.
17. Srinivasan, J., T. E. Cheatham III, ., D. A. Case. 1998. Continuum
solvent studies of the stability of DNA, RNA, and phosphoramidate-
DNA helices. J. Am. Chem. Soc. 120:9401–9409.
18. Aaqvist, J. 1990. Ion-water interaction potentials derived from free
energy perturbation simulations. J. Phys. Chem. 94:8021–8024.
19. Rodriguez-Gomez, D., E. Darve, and A. Pohorille. 2004. Assessing the
efficiency of free energy calculation methods. J. Chem. Phys. 120:
3563–3578.
20. Kumar, S., J. M. Rosenberg, ., P. A. Kollman. 1992. The weighted
histogram analysis method for free-energy calculations on biomole-
cules. I. The method. J. Comput. Chem. 13:1011–1021.
21. Curuksu, J., M. Zacharias,., K. Zakrzewska. 2009. Local and global
effects of strong DNA bending induced during molecular dynamics
simulations. Nucleic Acids Res. 37:3766–3773.
22. Curuksu, J., K. Zakrzewska, and M. Zacharias. 2008. Magnitude and
direction of DNA bending induced by screw-axis orientation: influence
of sequence, mismatches and abasic sites. Nucleic Acids Res. 36:2268–
2283.
23. Spiegel, K., A. Magistrato,., M. L. Klein. 2007. Azole-bridged dipla-
tinum anticancer compounds. Modulating DNA flexibility to escape
repair mechanism and avoid cross resistance. J. Phys. Chem. B.
111:11873–11876.
24. Zacharias, M. 2006. Minor groove deformability of DNA: a molecular
dynamics free energy simulation study. Biophys. J. 91:882–891.
25. Phillips, J. C., R. Braun, ., K. Schulten. 2005. Scalable molecular
dynamics with NAMD. J. Comput. Chem. 26:1781–1802.
26. Torrie, G. M., and J. P. Valleau. 1977. Nonphysical sampling distribu-
tions in Monte Carlo free-energy estimation: umbrella sampling.
J. Comput. Phys. 23:187–199.
27. Grossfield, A. WHAM: the weighted histogram analysis method,
version 2.0.4. http://membrane.urmc.rochester.edu/content/wham.
28. Roux, B. 1995. The calculation of the potential of mean force using
computer simulations. Comput. Phys. Commun. 91:275–282.
29. Mazur, A. K. 2006. Evaluation of elastic properties of atomistic DNA
models. Biophys. J. 91:4507–4518.
30. Pe´rez, A., F. J. Luque, and M. Orozco. 2012. Frontiers in molecular
dynamics simulations of DNA. Acc. Chem. Res. 45:196–205.
31. Liu, Z., B. Ensing, and P. B. Moore. 2010. Quantitative assessment of
force fields on both low-energy conformational basins and transition-
state regions of the (fj) space. J. Chem. Theory Comput. 7:402–419.
32. Vanden-Eijnden, E., and M. Venturoli. 2009. Revisiting the finite
temperature string method for the calculation of reaction tubes and
free energies. J. Chem. Phys. 130:194103–194117.
33. Weinan, E., W. Ren, and E. Vanden-Eijnden. 2002. String method for
the study of rare events. Phys. Rev. B. 66:052301.
34. Weinan, E., W. Ren, and E. Vanden-Eijnden. 2007. Simplified and
improved string method for computing the minimum energy paths in
barrier-crossing events. J. Chem. Phys. 126:164103–164108.Biophysical Journal 102(10) 2331–233835. Wiggins, P. A., T. van der Heijden,., P. C. Nelson. 2006. High flex-
ibility of DNA on short length scales probed by atomic force micros-
copy. Nat. Nanotechnol. 1:137–141.
36. Malina, J., M. Vojtiskova, ., T. W. Hambley. 2005. DNA adducts of
the enantiomers of the Pt(II) complexes of the ahaz ligand (ahaz¼3-
aminohexahydroazepine) and recognition of these adducts by HMG
domain proteins. Biochem. Biophys. Res. Commun. 332:1034–1041.
37. Juo, Z. S., T. K. Chiu,., R. E. Dickerson. 1996. How proteins recog-
nize the TATA box. J. Mol. Biol. 261:239–254.
38. Czapla, L., J. P. Peters, ., L. J. Maher, 3rd. 2011. Understanding
apparent DNA flexibility enhancement by HU and HMGB architectural
proteins. J. Mol. Biol. 409:278–289.
39. Rohs, R., X. Jin,., R. S. Mann. 2010. Origins of specificity in protein-
DNA recognition. Annu. Rev. Biochem. 79:233–269.
40. Margiotta, N., G. Natile, ., M. Coluccia. 2006. Sterically hindered
complexes of platinum(II) with planar heterocyclic nitrogen donors.
A novel complex with 1-methyl-cytosine has a spectrum of activity
different from cisplatin and is able of overcoming acquired cisplatin
resistance. J. Inorg. Biochem. 100:1849–1857.
41. Kasparkova, J., T. Suchankova, ., V. Brabec. 2010. Cytotoxicity,
cellular uptake, glutathione and DNA interactions of an antitumor
large-ring Pt II chelate complex incorporating the cis-1,4-diaminocy-
clohexane carrier ligand. Biochem. Pharmacol. 79:552–564.
42. Lovejoy, K. S., and S. J. Lippard. 2009. Non-traditional platinum
compounds for improved accumulation, oral bioavailability, and tumor
targeting. Dalton Trans. 48:10651–10659.
43. Macke, T. J., and D. A. Case. 1997. Modeling unusual nucleic acid
structures. In Molecular Modeling of Nucleic Acids. N. B. Leontis
and J. Santa Lucia, Jr., editors. American Chemical Society, Washing-
ton, DC. 379–393.
44. Scheeff, E. D., J. M. Briggs, and S. B. Howell. 1999. Molecular
modeling of the intrastrand guanine-guanine DNA adducts produced
by cisplatin and oxaliplatin. Mol. Pharmacol. 56:633–643.
45. Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD: visual molec-
ular dynamics. J. Mol. Graph. 14:33–38, 27–28.
46. Yao, S., and J. P. Plastaras. 1994. A molecular mechanics AMBER-type
force field for modeling platinum complexes of guanine derivatives.
Inorg. Chem. 33:6061–6077.
47. Brukner, I., M. Dlakic, ., D. Suck. 1993. Evidence for opposite
groove-directed curvature of GGGCCC and AAAAA sequence
elements. Nucleic Acids Res. 21:1025–1029.
48. Pe´rez, A., I. Marcha´n, ., M. Orozco. 2007. Refinement of the
AMBER force field for nucleic acids: improving the description of
a/g conformers. Biophys. J. 92:3817–3829.
49. Hornak, V., R. Abel,., C. Simmerling. 2006. Comparison of multiple
Amber force fields and development of improved protein backbone
parameters. Proteins. 65:712–725.
50. Hambley, T. W. 1998. van der Waals radii of Pt(II) and Pd(II) in molec-
ular mechanics models and an analysis of their relevance to the descrip-
tion of axial M.H(-C), M.H(-N), M.S, and M.M (M ¼ Pd(II) or Pt(II))
Interactions. Inorg. Chem. 37:3767–3774.
51. Cornell, W. D., P. Cieplak,., P. A. Kollman. 1995. A 2nd generation
force-field for the simulation of proteins, nucleic-acids, and organic-
molecules. J. Am. Chem. Soc. 117:5179–5197.
52. Bondi, A. 1964. van der Waals volumesþ radii. J. Phys. Chem. 68:441.
